Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Nearly 2,000 people have been vaccinated! "Lizhu Bio's recombinant novel coronavirus fusion protein vaccine" is being promoted and vaccinated in our city

Published Time:

2022-12-11

Recently

Jointly developed by Lizhu Bio and the Institute of Biophysics, Chinese Academy of Sciences

A new vaccine

—"Lizhu Bio Recombinant Novel Coronavirus Fusion Protein Vaccine"

has been officially promoted for vaccination in our city

Nearly 2,000 people have been vaccinated

At Lizhu Group Limin Pharmaceutical Factory, the reporter met Huang Wenhua, the factory director and senior engineer. According to him, Lizhu Bio launched the Lizhu Bio recombinant novel coronavirus fusion protein vaccine project in July 2020. In September 2022, the Lizhu Bio recombinant novel coronavirus fusion protein vaccine developed and produced by this project was officially included in the national COVID-19 immunization program.

Lizhu Bio Recombinant Novel Coronavirus Fusion Protein Vaccine

 Picture

 Picture

The Lizhu Bio recombinant novel coronavirus fusion protein vaccine is the world's first COVID-19 vaccine to pass Phase III clinical trials and achieve high protection against Omicron. Data shows that the vaccine has good safety and excellent protection. Based on two doses of inactivated vaccines, the absolute protection rate against Omicron after sequential booster vaccination with the Lizhu Bio recombinant novel coronavirus fusion protein vaccine is 61.35%, which is comparable to the effect of mRNA vaccine booster immunization, and is particularly suitable for the elderly, high-risk occupational groups and people with underlying diseases.

 Picture

Citizens register for COVID-19 vaccination at Shaoguan No. 2 People's Hospital.

Wang Weijie, member of the Party group of Wujiang District Health and Health Bureau:

To our understanding, currently, the sequential vaccination of people over 60 years old in Wujiang District mainly uses vaccines from Lizhu Bio and Anhui Zhifei. Both vaccines can produce good protective effects, effectively reducing the severity of infection in the elderly, and no adverse reactions have been reported. Therefore, for citizens who have not yet received a booster shot, we recommend sequential vaccination, or homologous vaccination. Based on current feedback, the effects of Lizhu Bio and Anhui Zhifei vaccines are better.

 Picture

Citizens receive COVID-19 vaccination at Shaoguan No. 2 People's Hospital.

Huang Wenhua:

The Lizhu Bio recombinant novel coronavirus fusion protein vaccine can be used as a third dose for booster immunization. People aged 18 and above who have completed the full course of basic immunization (meaning they have completed two doses of inactivated vaccine) for more than 3 months can choose to receive this vaccine. Like other vaccines, there are some people who are not suitable for vaccination, such as those with a history of serious allergic reactions to vaccines, pregnant and lactating women, etc. Citizens should follow the guidance of medical staff before vaccination.

Currently

Some vaccination sites in counties (cities, districts) across the city

can choose to vaccinate with the Lizhu Bio recombinant novel coronavirus fusion protein vaccine

Citizens in need can go to the vaccination sites to learn more and get vaccinated

Text: Shaoguan Daily All-Media Reporter Du Haitao

Pictures/Videos: He Lijian

Editor: Li Jianqun

Editor in charge: Wang Lurong

 

Transferred from: Shaoguan News Network